Table 3

Predictors of mortality at 1 year post-TAVI in the overall study population

Univariate
OR (95% CI)
P valueMultivariate
OR (95% CI)*
P value
Age (years)0.997 (0.973 to 1.021)0.7791.002 (0.972 to 1.033)0.903
Female gender0.796 (0.591 to 1.072)0.1341.156 (0.811 to 1.646)0.422
Cardiac history
 Prior MI1.333 (0.923 to 1.924)0.1250.979 (0.638 to 1.502)0.922
 Prior cardiac surgery†1.220 (0.882 to 1.687)0.2290.881 (0.588 to 1.320)0.540
 Prior stroke1.062 (0.707 to 1.597)0.7710.875 (0.561 to 1.364)0.556
Comorbidities
 AF2.140 (1.584 to 2.892)<0.0011.758 (1.267 to 2.439)0.001
 Hypertension1.390 (0.705 to 2.743)0.3420.879 (0.427 to 1.808)0.725
 CAD1.638 (1.188 to 2.258)0.0031.559 (1.054 to 2.306)0.026
 Mitral valve insufficiency (>II°)1.225 (0.624 to 2.404)0.5550.929 (0.453 to 1.905)0.841
 Porcelain aorta1.194 (0.864 to 1.649)0.2831.117 (0.786 to 1.588)0.537
 Pulmonary hypertension1.475 (1.074 to 2.027)0.0161.353 (0.958 to 1.909)0.086
 COPD1.383 (0.980 to 1.950)0.0651.156 (0.792 to 1.687)0.451
 Diabetes mellitus1.861 (1.354 to 2.559)<0.0011.238 (0.876 to 1.750)0.226
 Kidney insufficiency1.156 (0.721 to 1.854)0.5461.458 (1.021 to 2.084)0.038
NYHA class III or IV2.233 (1.372 to 3.634)0.0011.824 (1.099 to 3.027)0.020
LVEF (%)0.976 (0.966 to 0.987)<0.0010.985 (0.972 to 0.998)0.020
Peak AV gradient (mm Hg)0.989 (0.983 to 0.995)0.0011.000 (0.982 to 1.017)0.965
Mean AV gradient (mm Hg)0.983 (0.974 to 0.993)<0.0010.994 (0.969 to 1.021)0.676
  • *Adjusted for all other variables.

  • †Not including percutaneous coronary intervention.

  • AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; TA, transapical; TF, transfemoral.